Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease
- Authors
- Kim, Hakyoung; Yang, Dae Sik; Kim, Sun Myung
- Issue Date
- Jun-2023
- Publisher
- Blackwell Pub. Asia
- Keywords
- local control; metastasis; nonsmall cell lung cancer; radiotherapy; survival
- Citation
- Asia-Pacific Journal of Clinical Oncology, v.19, no.3, pp 385 - 391
- Pages
- 7
- Indexed
- SCIE
SCOPUS
- Journal Title
- Asia-Pacific Journal of Clinical Oncology
- Volume
- 19
- Number
- 3
- Start Page
- 385
- End Page
- 391
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62006
- DOI
- 10.1111/ajco.13880
- ISSN
- 1743-7555
1743-7563
- Abstract
- Aim
Prior clinical data have shown a significant survival benefit of consolidative local radiotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC). Therefore, this study aimed to evaluate the impact of consolidative high-dose thoracic radiotherapy on local control rates and survivals in patients with limited metastatic NSCLC, especially focusing on oligo-progressive disease.
Methods
We retrospectively reviewed the medical records of 45 patients with limited metastatic NSCLC who received consolidative high-dose thoracic radiotherapy at the Korea University Guro Hospital between March 2015 and December 2020. In the current study, we included patients who showed partial response, stable disease, or oligo-progressive disease on tumor response evaluation after systemic treatment. All patients underwent stereotactic body radiation therapy (23 patients) or intensity-modulated radiation therapy (IMRT, 22 patients).
Results
The median follow-up time was 42 months (range: 5–88 months). The overall 2-year disease-free survival (DFS) and overall survival (OS) rates were 80.7% and 88.4%, respectively. Among the 45 patients, only two patients treated with IMRT showed in-field local recurrence. There was no local failure among the patients who showed oligo-progressive disease after systemic treatment. In addition, the response to systemic treatment was not a significant factor for either DFS or OS rates (p = .471 and p = .414, respectively) in univariate analysis.
Conclusions
Consolidative high-dose thoracic radiotherapy improves local control rates and helps achieve long-term survival in patients with limited metastatic NSCLC. It is also effective and should be considered in patients with oligo-progressive disease after systemic treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Radiation Oncology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.